Human immunodeficiency virus and liver disease forum 2010: Conference proceedings

✍ Scribed by Kenneth E. Sherman; David L. Thomas; Raymond T. Chung

• Book ID: 102243328
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 304 KB
• Volume: 54
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.24651

✦ Synopsis

Liver disease continues to represent a critical mediator of morbidity and mortality in those with human immunodeficiency virus (HIV) infection. The frequent presence and overlap of concomitant injurious processes, including hepatitis C virus and hepatitis B virus infections, hepatoxicity associated with antiretroviral therapeutic agents, alcohol, and other toxins, in the setting of immunosuppression lead to rapid fibrotic progression and early development of end-stage liver disease. This conference summary describes the proceedings of a state-of-the-art gathering of international experts designed to highlight the status of current research in epidemiology, natural history, pathogenesis, and treatment of HIV and liver disease. (HEPATOLOGY 2011;54:2245-2253) E pidemiologic and natural history studies have clearly demonstrated the significant role played by liver-associated morbidity and mortality among those infected with human immunodeficiency virus (HIV) in the post-HAART (highly active antiretroviral therapy) era. The reasons for this are complex, but include coinfections with hepatitis B virus (HBV), hepatitis C virus (HCV), drug-related hepatotoxicity, alcohol, and a modified cytokine milieu that contributes to increased rates of fibrotic progression and advanced liver disease. There is a mounting body of evidence that HIV directly infects, or through its